StemBioSys

StemBioSys

The Next Evolution in Cell Culture

Print
Claim My Business
Min Investment
$300
Location
San Antonio , TX
Expected Close Date
September 03, 2024
Target Raise
$15.00K-$3.00M
Security Price
$3
Website
stembiosys.com
Number of Employees
9
Cash
$111,047
Revenue
$550,450
Short Term Debt
$1,586,281
Cost of Goods
$0
Long Term Debt
$405,497
Net Income
$-1,537,261

Company Description

StemBioSys® is a biomedical company whose advanced cell technologies can test drugs more efficiently and accurately without using animal models.

Key Deal Facts

StemBioSys® innovates drug testing with patented lab tools allowing the testing of new products with cultured human cells, not from embryos, replacing less accurate chemical tests & experimental animal models.

StemBioSys® has established a strong foothold in the biopharmaceutical, academic, and government markets with pioneering products such as CELLvo™ Atrial Cardiomyocytes and our patented Matrix Plus™.
Amount Raised : $70,902
Reveal the Score by Voting
_
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.
Valuation

Research Reports

No reports have been submitted

Become a Reporter

0 Comments